Be part of the knowledge.™
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Upcoming Events

Elevating AAV Care: Expert Strategies for Optimal Patient Outcomes

Discover the latest advances in ANCA-associated vasculitis (AAV). Tune in for valuable insights from our experts!

Live Meeting
1.00 available credits
Information
May 24, 2024
13:45 - 14:45 CEST
Stockholmsmässan
Mässvägen 1 Älvsjö, 125 80 Stockholm, Sweden, Room: A5
ReachMD Healthcare Image
Details
Presenters
Comments

  • Overview

    Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a complex autoimmune disease. This condition can lead to life-threatening complications that primarily affect kidney function. Join renowned experts, Drs. Annette Bruchfeld, Stephen McAdoo, and Andreas Kronbichler, as they discuss insightful case presentations to unravel the latest advances in AAV induction and maintenance treatments and describe innovative approaches to managing patients with AAV.

    Click here to register for the ERA Congress.

  • Program Schedule*

    13:45  Welcome

    13:49  Advancing AAV Care: A Patient-Centered Approach to Personalized Treatment and Improved Outcomes Presented by Dr. Andreas Kronbichler

    13:59  2024 KDIGO Practice Guideline for the Management of AAV Presented by Dr. Annette Bruchfeld

    14:02  Unveiling the Therapeutic Landscape of AAV: From Current Standards to Emerging Breakthroughs (Case Presentation 1) Presented by Dr. Stephen McAdoo

    14:17  Unveiling the Therapeutic Landscape of AAV: From Current Standards to Emerging Breakthroughs (Case Presentation 2) Presented by Dr. Annette Bruchfeld

    14:23  Panel Discussion and Take-Home Messages

    14:35  Question & Answer Session

    14:45  Adjourn

    *Subject to Change 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Annette Bruchfeld, MD, PhD 
    Professor of Nephrology
    Linköping University
    Guest Professor
    Karolinska Institutet
    Unit of Renal Medicine
    Stockholm, Sweden

    Dr. Bruchfeld has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Alexion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, and CSL Vifor

    Faculty:
    Stephen McAdoo, MD
    Consultant Nephrologist
    Imperial College Healthcare NHS Trust
    London, United Kingdom

    Dr. McAdoo has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: CSL Vifor, GSK
    Research: AstraZeneca, Therini Bio

    Andreas Kronbichler, MD
    Assistant Professor
    Medical University Innsbruck
    Innsbruck, Austria

    Dr. Kronbichler has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AstraZeneca, CSL Vifor, Delta4, GSK, Otsuka
    Research: CSL Vifor

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Howard Green has nothing to disclose.
    • Hany Ibrahim, MD, has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Kathleen Sheridan, PhD, has nothing to disclose.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify the role of the alternative complement pathway in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) 
    • Evaluate the frequency of relapse and impact of medication-related toxicity associated with the use of traditional standard of care medications in the management of patients with AAV
    • Develop patient-centered and evidence-based induction and maintenance treatment strategies to achieve sustained remission and mitigate treatment-associated toxicity in patients with AAV

  • Target Audience

    This activity is designed to meet the educational needs of the practicing nephrologist and rheumatologist.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Details
Presenters
Comments
Recommended

  • Overview

    Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a complex autoimmune disease. This condition can lead to life-threatening complications that primarily affect kidney function. Join renowned experts, Drs. Annette Bruchfeld, Stephen McAdoo, and Andreas Kronbichler, as they discuss insightful case presentations to unravel the latest advances in AAV induction and maintenance treatments and describe innovative approaches to managing patients with AAV.

    Click here to register for the ERA Congress.

  • Program Schedule*

    13:45  Welcome

    13:49  Advancing AAV Care: A Patient-Centered Approach to Personalized Treatment and Improved Outcomes Presented by Dr. Andreas Kronbichler

    13:59  2024 KDIGO Practice Guideline for the Management of AAV Presented by Dr. Annette Bruchfeld

    14:02  Unveiling the Therapeutic Landscape of AAV: From Current Standards to Emerging Breakthroughs (Case Presentation 1) Presented by Dr. Stephen McAdoo

    14:17  Unveiling the Therapeutic Landscape of AAV: From Current Standards to Emerging Breakthroughs (Case Presentation 2) Presented by Dr. Annette Bruchfeld

    14:23  Panel Discussion and Take-Home Messages

    14:35  Question & Answer Session

    14:45  Adjourn

    *Subject to Change 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Annette Bruchfeld, MD, PhD 
    Professor of Nephrology
    Linköping University
    Guest Professor
    Karolinska Institutet
    Unit of Renal Medicine
    Stockholm, Sweden

    Dr. Bruchfeld has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Alexion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, and CSL Vifor

    Faculty:
    Stephen McAdoo, MD
    Consultant Nephrologist
    Imperial College Healthcare NHS Trust
    London, United Kingdom

    Dr. McAdoo has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: CSL Vifor, GSK
    Research: AstraZeneca, Therini Bio

    Andreas Kronbichler, MD
    Assistant Professor
    Medical University Innsbruck
    Innsbruck, Austria

    Dr. Kronbichler has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AstraZeneca, CSL Vifor, Delta4, GSK, Otsuka
    Research: CSL Vifor

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Howard Green has nothing to disclose.
    • Hany Ibrahim, MD, has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Kathleen Sheridan, PhD, has nothing to disclose.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify the role of the alternative complement pathway in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) 
    • Evaluate the frequency of relapse and impact of medication-related toxicity associated with the use of traditional standard of care medications in the management of patients with AAV
    • Develop patient-centered and evidence-based induction and maintenance treatment strategies to achieve sustained remission and mitigate treatment-associated toxicity in patients with AAV

  • Target Audience

    This activity is designed to meet the educational needs of the practicing nephrologist and rheumatologist.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Recommended

Schedule12 Dec 2024
PrevNext

Program Chapters

Segment Chapters

Playlist:

Recommended